Phibro Animal Health Corporation $PAHC Stake Trimmed by Globeflex Capital L P

Globeflex Capital L P lowered its stake in Phibro Animal Health Corporation (NASDAQ:PAHC) by 7.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 215,257 shares of the company’s stock after selling 16,242 shares during the quarter. Phibro Animal Health makes up 1.2% of Globeflex Capital L P’s investment portfolio, making the stock its 13th largest holding. Globeflex Capital L P owned about 0.53% of Phibro Animal Health worth $8,042,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. 1620 Investment Advisors Inc. boosted its position in Phibro Animal Health by 77.4% during the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after acquiring an additional 295 shares during the period. Farther Finance Advisors LLC boosted its position in Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after acquiring an additional 386 shares during the period. Rothschild Investment LLC boosted its position in Phibro Animal Health by 2,500.0% during the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after acquiring an additional 1,000 shares during the period. Hughes Financial Services LLC acquired a new stake in Phibro Animal Health during the 3rd quarter worth about $40,000. Finally, iSAM Funds UK Ltd acquired a new stake in Phibro Animal Health during the 3rd quarter worth about $61,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Stock Up 3.9%

Shares of Phibro Animal Health stock opened at $33.04 on Friday. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of 14.18, a P/E/G ratio of 0.48 and a beta of 0.46. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. Phibro Animal Health Corporation has a 52-week low of $22.85 and a 52-week high of $60.08. The stock has a 50-day simple moving average of $46.67 and a 200-day simple moving average of $45.23.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.04. The business had revenue of $383.54 million during the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, equities research analysts expect that Phibro Animal Health Corporation will post 3.07 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.5%. The ex-dividend date is Wednesday, June 3rd. Phibro Animal Health’s payout ratio is currently 20.60%.

Insider Activity

In other news, CEO Jack Bendheim sold 4,528 shares of Phibro Animal Health stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $48.49, for a total transaction of $219,562.72. Following the completion of the sale, the chief executive officer directly owned 56,152 shares in the company, valued at $2,722,810.48. The trade was a 7.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 74,928 shares of company stock worth $4,017,273. 50.13% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PAHC. Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research report on Friday, February 6th. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Weiss Ratings lowered Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 8th. Finally, Citigroup decreased their price objective on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $38.80.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.